ChemoCentryx, Inc.
Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
Last updated:
Abstract:
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
Status:
Grant
Type:
Utility
Filling date:
24 Sep 2018
Issue date:
19 Apr 2022